• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Usefulness of Triglyceride-glucose index for detecting prevalent atrial fibrillation in a type 2 diabetic population
CONCLUSION: Our data supported a linear and robust correlation between TyG and the prevalent AF in a diabetic population. Moreover, our results implicated the potential usefulness of TyG to refine the detection of prevalent AF in a diabetic population.PMID:36093727 | DOI:10.1080/00325481.2022.2124088
Source: Postgraduate Medicine - September 12, 2022 Category: Internal Medicine Authors: Wenrui Shi Mu Qin Shaohui Wu Kai Xu Qidong Zheng Xu Liu Source Type: research

Sex-disparities in risk factors and atherosclerosis cardiovascular disease in diabetic patients
Conclusion: Among diabetic people, compared to males, females had a higher comorbid burden but received less optimal treatment, which might partly explain their higher prevalence of composite ASCVD and CHD.PMID:33874831 | DOI:10.1080/00325481.2021.1917930
Source: Postgraduate Medicine - April 20, 2021 Category: Internal Medicine Authors: Yue Sun Dong Yan Lijuan Cui Guiping Li Yan Sun Zirui Hao Source Type: research

Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Authors: Guthrie R Abstract Review of:Rosenstock J, Perkovic V, Johansen, OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139:351-361.These two papers describe the findings from the CARMELINA trial (Cardiovascular and Renal Microvascular Outco...
Source: Postgraduate Medicine - March 15, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Management of hypoglycemia in older adults with type 2 diabetes.
This article highlights the issues faced by older people with T2D, the risk factors for hypoglycemia in this population, and the challenges faced by health care providers regarding glycemic management in this patient group. PMID: 30724638 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - February 8, 2019 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Practice Pearl: Liraglutide and Cardiovascular and Renal Events in Type 2 Diabetes.
Authors: Guthrie R Abstract Review of: Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322. Mann J, Orsted D, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 839-848. This comprehensive research project, LEADER, led to two reports, one focusing on the effect of liraglutide on cardiovascular events, and the second one reporting on the renal effects on the same study population. The study group included 9340 patients with type 2 diabetes. Patients were required to have type 2 diabet...
Source: Postgraduate Medicine - January 21, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Canagliflozin and cardiovascular and renal events in type 2 diabetes.
This study expands the scope of SGLT-2 inhibitor therapy to prevent cardiovascular disease in diabetic patients beyond those with preexisting cardiovascular disease studied in the previous empagliflozin study, raising the question as to whether SGLT-2 inhibitor therapy should be considered appropriate for most, if not all, type 2 diabetes patients, not only to control hyperglycemia but also to reduce cardiovascular and renal events. PMID: 29297732 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - January 5, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Authors: Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS Abstract Diabetes mellitus is a growing in exponential proportions. If the current growth trend continues, it may result in every third adult in the United States having diabetes mellitus by 2050, and every 10(th) adult worldwide. Type 2 diabetes mellitus (T2DM) confers a 2- to 3-fold increased risk of cardiovascular (CV) events compared with non-diabetic patients, and CV mortality is responsible for around 80% mortality in this population. Patients with T2DM can have other features of insulin resistance-metabolic syndrome like hypertension, lipid ab...
Source: Postgraduate Medicine - July 29, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
CONCLUSION: These findings suggest that in T2DM subjects on metformin, BQR therapy may represent an effective strategy for reducing CVD risk. PMID: 27687032 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - October 2, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Empagliflozin Reduces Cardiovascular Events and Mortality in Type 2 Diabetes.
Authors: Guthrie R Abstract Review of: Zinnam, B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015; 373: 2117-2128. Patients were required to have a history of established cardiovascular disease, along with Type 2 Diabetes but were either not on antidiabetic therapy for the preceding 12 weeks, with a glycated hemoglobin level between 7% and 9%, or were on stable antidiabetic therapy for the preceding 12 weeks, with a glycated hemoglobin between 7.0% and 10.0%. Patients were randomized in a 1:1:1 ratio to either empagliflozin ...
Source: Postgraduate Medicine - April 6, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Authors: Green JB Abstract Patients with diabetes have approximately a 2-fold increase in the risk for coronary heart disease, stroke, and death from vascular causes compared with patients who do not have diabetes. Interventions targeted at modifiable risk factors, such as smoking cessation and management of hypertension and dyslipidemia, reduce the risk of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). Paradoxically, large randomized studies have failed to conclusively show that intensively lowering glucose reduces CVD event rates in patients with T2DM, despite pathophysiologic and ...
Source: Postgraduate Medicine - November 28, 2014 Category: Internal Medicine Tags: Postgrad Med Source Type: research